Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Fertility and Sterility

• Publication date

  1998-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0015-0282(97)00524-4PMID 8150109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standardization of symbols in clinical pharmacology

  2004cited by this paper
• Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers.

  1993cited by this paper
• Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH.

  1992cited by this paper
• Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH.

  1992cited by this paper
• FSH isoforms, radioimmunoassays, bioassays, and their significance.

  1992cited by this paper
• In vitro bioassays of follicle-stimulating hormone: methods and clinical applications

  1991cited by this paper
• The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and their Effect on Glycoprotein Properties

  1991cited by this paper
• Metabolic clearance of human follicle-stimulating hormone assessed by radioimmunoassay, immunoradiometric assay, and in vitro Sertoli cell bioassay.

  1991cited by this paper
• Clinical review 4: Diagnosis and treatment of isolated gonadotropin-releasing hormone deficiency in men.

  1990cited by this paper
• Granulosa cell aromatase bioassay for follicle-stimulating hormone.

  1989cited by this paper
• Naturally occurring antihormones: secretion of FSH antagonists by women treated with a GnRH analog.

  1988cited by this paper
• Clinical-pharmacological studies on human menopausal gonadotrophin.

  1988cited by this paper
• Serum bioactive follicle-stimulating hormone during the human menstrual cycle and in hyper- and hypogonadotropic states: application of a sensitive granulosa cell aromatase bioassay.

  1986cited by this paper
• Twin pregnancy after pituitary desensitisation with LHRH agonist and pure FSH.

  1985cited by this paper
• Heterogeneity of rat FSH by chromatofocusing: studies on serum FSH, hormone released in vitro and metabolic clearance rates of its various forms.

  1985cited by this paper
• A role for glycosylation of the alpha subunit in transduction of biological signal in glycoprotein hormones.

  1985cited by this paper
• Factors influencing pregnancy rates following in vitro fertilization and embryo transfer.

  1985cited by this paper
• Existence of multiple forms of follicle-stimulating hormone within the anterior pituitaries of cynomolgus monkeys.

  1984cited by this paper
• The Biochemistry of Glycoproteins and Proteoglycans

  1980cited by this paper
• Carbohydrate Recognition Systems for Receptor-Mediated Pinocytosis

  1980cited by this paper
• Human pituitary follicle-stimulating hormone: distribution, plasma clearance and urinary excretion as determined by radioimmunoassay.

  1970cited by this paper
• INDUCTION OF OVULATION *

  1966cited by this paper
• Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin.

  1953cited by this paper

• Commentary: FSH receptor N680S genotype-guided gonadotropin choice increases cumulative pregnancy and live birth rates after in vitro fertilization

  2026cites this paper
• The influence of the pharmaceutical industry on the development of gonadotrophins and ovarian stimulation protocols in assisted reproductive technologies

  2025cites this paper
• Use of new recombinant proteins for ovarian stimulation in ruminants

  2023cites this paper
• Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?

  2023cites this paper
• Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women

  2022cites this paper
• Missed IVF medications

  2021cites this paper
• Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats

  2021cites this paper
• Extended Injection Intervals of Gonadotropins With Super�cial Skin Administration In Ivf Treatment Is both Cost-Effective and Patient-Friendly

  2020cites this paper
• Advances in ART Pharmacology: Drug Delivery Systems and the Pipeline

  2020cites this paper
• Influence of human chorionic gonadotrophin during ovarian stimulation: an overview

  2020cites this paper
• Small Molecule Follicle-Stimulating Hormone Receptor Agonists and Antagonists

  2019cites this paper
• Effect of Recombinant Follicle Stimulating Hormone and Recombinant Luteinizing Hormone on Maturation of Mammalian Oocytes in Vitro

  2017cites this paper
• A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials

  2017cites this paper
• Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs, and recombinant gonadotropins

  2017cites this paper
• Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

  2016cites this paper
• Clinical Applications of Gonadotropins in the Male.

  2016cites this paper
• Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.

  2016cites this paper
• Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin

  2016cites this paper
• Эффективность применения гонадотропина Фоллитроп для стимуляции яичников в протоколах контролируемой индукции овуляции

  2016cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Phase 1 safety , tolerability , and pharmacokinetic study of single ascending doses of XM 17 ( recombinant human follicle-stimulating hormone ) in downregulated healthy women

  2015cites this paper
• Different pharmacokinetic and pharmacodynamic properties of recombinant follicle‐stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non‐human cell line

  2014cites this paper
• Biosimilar recombinant follicle stimulating hormones in infertility treatment

  2014cites this paper
• Comparison of recombinant human follicle stimulating hormone (rhFSH), human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) on semen parameters after varicocelectomy: a randomized clinical trial

  2012cites this paper
• Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome

  2012cites this paper
• Does the addition of LH activity to FSH make gonadotrophins more superior? A systematic review and meta-analysis

  2012cites this paper
• Abdominal mesotherapy injection extended the absorption of follicle-stimulating hormone.

  2011cites this paper
• A 30-Day Preclinical Safety Evaluation Study of Recombinant Human Follicle-Stimulating Hormone in Female Rhesus Monkeys

  2011cites this paper
• Recombinant human follicular stimulating hormone and recombinant human luteinizing hormone in a 2:1 ratio combination. Pharmacological characteristics and clinical applications

  2010cites this paper
• Papel do Hormônio Folículo Estimulante na foliculogênese in vivo e in vitro Role of Follicle Stimulating Hormone in folliculogenesis in vivo and in vitro

  2009cites this paper
• Praktisches Vorgehen bei gestörter Ovarfunktion und damit assoziierten Phänomenen

  2009cites this paper
• Studies on pharmacokinetics of recombinant human follicle stimulating hormone

  2009cites this paper
• Drug delivery for in vitro fertilization: rationale, current strategies and challenges.

  2009cites this paper
• Benefits of luteinizing hormone activity in ovarian stimulation for IVF.

  2009cites this paper
• Recombinant human FSH and recombinant human LH in a 2:1 ratio combination: a new tool for ovulation induction

  2009cites this paper
• Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.

  2009cites this paper
• Role of Follicle Stimulating Hormone in folliculogenesis in vivo and in vitro.

  2009cites this paper
• Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2 : 1 combination: two phase I, randomised, crossover studies

  2008cites this paper
• Endocrine characteristics of ART cycles

  2008cites this paper
• The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.

  2006cites this paper
• Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): A comparative study

  2005cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

  2005cites this paper
• Molecular pharmacology of gonadotropins

  2005cites this paper
• Follicle-Stimulating Hormone in Clinical Practice

  2004cites this paper
• Receptor‐mediated transcytosis of follicle‐stimulating hormone through the rat testicular microvasculature

  2004cites this paper
• Male Hypogonadism

  2004cites this paper
• Recombinant human follicle-stimulating hormone: a controversial issue – without controversy

  2004cites this paper
• Stimulation of Spermatogenesis in Hypogonadotropic Men

  2004cites this paper
• Recombinant FSH vs. urinary FSH for ovarian stimulation in in vitro fertilization.

  2003cites this paper
• A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome.

  2003cites this paper
• Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome.

  2003cites this paper
• The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.

  2001cites this paper
• Human Recombinant Follicle Stimulating Hormone (Follitropin‐α)

  2000cites this paper
• Definition and measurement of follicle stimulating hormone.

  2000cites this paper
• Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins.

  2000cites this paper
• Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men.

  1999cites this paper
• Recombinant gonadotrophins

  1999cites this paper
• Clinical efficacy of recombinant gonadotrophins

  1999cites this paper
• What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins.

  1999cites this paper
• Clinical efficacy of recombinant gonadotrophins

  1999cites this paper
• Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle.

  1998cites this paper
• Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone.

  1998cites this paper
• Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration.

  1998cites this paper
• Outcome comparison of in vitro fertilization treatment with highly purified subcutaneous follicle-stimulating hormone (Fertinex, a urofollitropin) versus intramuscular menotropins.

  1998cites this paper
• Follitropin alpha in infertility: a review.

  1998cites this paper
• The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.

  1998cites this paper
• Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Recombinant Human FSH Study Group.

  1998cites this paper
• Recombinant Follicle‐Stimulating Hormone: New Biotechnology for Infertility

  1998cites this paper
• Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction?

  1998cites this paper
• Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone.

  1998cites this paper
• Follitropin Alpha in Infertility

  1998influential citation
• Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility Recombinant Human FSH Product Development Group*

  1998cites this paper
• Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay.

  1998cites this paper
• Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics.

  1998cites this paper
• Biotechnological Drugs for Reproductive Disorders

  1997cites this paper
• Biotechnological drugs for reproductive disorders: a review of developments.

  1997cites this paper
• Chapter 31. To Market, To Market - 1996

  1997cites this paper
• Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations.

  1997cites this paper
• [Clinical use of recombinant gonadotropins (FSH, LH, hCG)].

  1997cites this paper
• Serum FSH levels in women with polycystic ovary syndrome during ovulation induction using down-regulation and urofollitropin.

  1997cites this paper
• Recombinant technique and gonadotropins production: new era in reproductive medicine.

  1996cites this paper
• The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.

  1996cites this paper
• Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.

  1996cites this paper
• Recombinant Technique and Gonadotropins Production: New Era in Reproductive Medicine

  1996cites this paper
• Current concepts on ultradian rhythms of luteinizing hormone secretion in the human.

  1996cites this paper
• Clinical assessment of human gonadotrophins produced by recombinant DNA technology.

  1996cites this paper
• Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy.

  1996influential citation
• The relevance of pharmacokinetics in the development of biotechnology products

  1996cites this paper
• Pharmacokinetics of gonadotropin therapy

  1996cites this paper
• Comprehensive Pharmacokinetics of Urinary Human Follicle Stimulating Hormone in Healthy Female Volunteers

  1995cites this paper
• [Recombinant FSH. Characteristics and therapeutical values].

  1995cites this paper